Back to Resources
Market Highlights
-
BeiGene highlighted Brukinsa’s commercial growth and pipeline updates at a healthcare conference.
-
AstraZeneca touted the U.S. approval of Calquence plus Venclexta and continued commercial growth.
-
Eli Lilly announced the approval of Jaypirca for relapsed/refractory chronic lymphocytic leukemia.
-
Genentech promoted the U.S. approval of Lunsumio Velo.
-
Ipsen discussed the voluntary U.S. withdrawal of Tazverik for relapsed or refractory follicular lymphoma and highlighted the brand at a healthcare conference.
-
AbbVie and Genentech announced the FDA approval of the fixed-duration Venclexta plus Calquence regimen for chronic lymphocytic leukemia.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com